We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Chip Developed to Detect Cancer in 30 Minutes

By LabMedica International staff writers
Posted on 07 Jun 2018
Print article
Image: The microfluidic chip developed to detect proteins (Photo courtesy of National Chung Cheng University).
Image: The microfluidic chip developed to detect proteins (Photo courtesy of National Chung Cheng University).
A compact microfluidic chip with integrated impedance biosensor for protein pre-concentration and detection has been developed.

The new technology can detect tumor markers in the bloodstream of cancer patients when they are still in the early stages of the disease. Furthermore, cancer screening in general hospitals usually takes at least one day to test different bodily substances, while the chip requires just five microliters of blood or urine.

Scientists at the National Chung Cheng University (Chiayi, Taiwan) have developed a low-cost, compact biochip is designed and fabricated for protein detection. Nanofractures formed by self-assembled gold nanoparticles at junction gaps are applied for ion enrichment and depletion to create a trapping zone when electroosmotic flow occurs in microchannels.

An impedance measurement module is implemented based on the lock-in amplifier technique to measure the impedance change during antibody growth on the gold electrodes, which is caused by trapped proteins in the detection region. The impedance measurement results confirm the presence of trapped proteins. Distinguishable impedance profiles measured at frequencies in the range of 10–100 kHz, for the detection area taken before and after the presence of proteins validate the performance of the proposed system. The chip works at a low voltage of about 36 volts, so that it can use general-purpose batteries or household electricity to analyze the sample.

Chun-Ping Jen, PhD, the leading study author, said, “People with cancer have some specific proteins in their bodies, which are called tumor markers. However, the proteins cannot usually be detected until they are in a large concentration during the middle and later stages of cancer. The chip, which took five years to develop, will be fitted into a handheld medical device than can also be used in the detection of other diseases. The study was originally published in the September 2018 issue of the journal Biomicrofluidics.

Related Links:
National Chung Cheng University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.